Hemorrhage Treatment Report of Patients Suffering from Glanzmann’s Thrombasthenia Resulting Hospitalization from 2006 to 2011 at Mofid Children’s Hospital
Journal Title: Iranian Journal of Blood and Cancer - Year 2014, Vol 6, Issue 3
Abstract
Background: The present study evaluated treatment outcomes and the treatment indexes among Glanzmann’s patients in Mofid Children’s Hospital, Tehran, Iran. Patients and Methods: A retrospective cross-sectional study was performed to evaluate the treatment protocols on 15 Glanzmann’s patients with bleeding therapeutic records in Mofid Children’s Hospital, Tehran, Iran, from 2006 to 2011. Results: The total recombinant factor VIIa used was 137mg and the total infused platelet concentrates was 68 units, with platelets used in order being: apheresis platelets, leukoreduced pooled platelets, leukoreduced platelets, and random donor platelets with 35, 16, 13 and 4 units respectively. In 90% of bleeding sequences, leukoreduced platelets were available and the average admission per patient was 3.46 times, the average leukoreduced platelets consumption per patient was 4.26 units and the average use of recombinant factor VIIa per patient was 9.13mg. Other Indexes included the average hospitalization per patient per year of 0.69% times, the average consumption of non- random platelet per patient per year of 0.85% units, the average consumption of recombinant factor VIIa per patient per year of 1.83mg, the average consumption of non random platelet for any hemorrhage incidence or elective surgery of 1.3 units, and the average consumption of recombinant factor VIIa for any hemorrhage incidence of 2.8mg. Conclusion: By extracting the consumption of therapeutical products to treat Glanzmann’s thrombasthenia in our center we could estimate the future treatment needs of our medical center. More thorough investigation of patients from different age groups is recommended to achieve more reliable results. Key Words: Glanzmann’s thrombasthenia, platelet, rFVIIa, treatment index.
Authors and Affiliations
Peyman Eshghi, Alireza Jenabzadeh, Behnaz Habibpanah
Keywords
Related Articles
- EP ID EP364642
- DOI -
- Views 63
- Downloads 0
Pediatric Meduloblastoma and the Prognostic Value of MIB-1 Proliferative Factor
Background: Medulloblastoma is the most common malignant brain tumor in children. The important factors in predicting survival are the extent of disease, proliferation index of the tumor cells, histopathologic class and...
Short-term Chelating Efficacy of Deferoxamine in Iron Overloaded Rat Hepatocytes
Abstract Background: Iron overload is a clinical consequence of repeated blood transfusions and causes significant organ damage, morbidity, and mortality in the absence of proper treatment. The primary targets of Iron ch...
Prevalence of Gastrointestinal Tract Lesions in Patients with Iron-Deficiency Anemia
Background: the Iron deficiency anemia (IDA) is a common cause of referral to medical departments. Chronic gastrointestinal (GI) blood loss is important cause of IDA and also an alarming sign of serious underlying diseas...
A Review of Procedures Involved in Human Umbilical Cord Blood Banking and Transplantation
Cord blood hematopoietic stem cells are widely used as an alternative source for hematopoietic stem cells transplant. Increasing rate of patients who need hematopoietic stem cells transplant and many advantages of cord b...
Main Determinants of Severe Neutropenia in Patients with Solid Tumors Receiving Adjuvant Chemotherapy
Background:Chemotherapy-induced neutropenia as a major toxicity of systemic chemotherapy is commonly associated with substantial mortality and morbidity, and thus identifying its determinants is necessary. This study was...